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AbstrACt
Introduction A broad range of stakeholders have 
called for randomised evidence on the potential 
clinical benefits and harms of proton therapy, a type 
of radiation therapy, for patients with breast cancer. 
Radiation therapy is an important component of 
curative treatment, reducing cancer recurrence and 
extending survival. Compared with photon therapy, the 
international treatment standard, proton therapy reduces 
incidental radiation to the heart. Our overall objective 
is to evaluate whether the differences between proton 
and photon therapy cardiac radiation dose distributions 
lead to meaningful reductions in cardiac morbidity and 
mortality after treatment for breast cancer.
Methods We are conducting a large scale, multicentre 
pragmatic randomised clinical trial for patients with 
breast cancer who will be followed longitudinally for 
cardiovascular morbidity and mortality, health-related 
quality of life and cancer control outcomes. A total of 
1278 patients with non-metastatic breast cancer will be 
randomly allocated to receive either photon or proton 
therapy. The primary outcomes are major cardiovascular 
events, defined as myocardial infarction, coronary 
revascularisation, cardiovascular death or hospitalisation 
for unstable angina, heart failure, valvular disease, 
arrhythmia or pericardial disease. Secondary endpoints 
are urgent or unanticipated outpatient or emergency 
room visits for heart failure, arrhythmia, valvular disease 
or pericardial disease. The Radiotherapy Comparative 
Effectiveness (RadComp) Clinical Events Centre will 
conduct centralised, blinded adjudication of primary 
outcome events.
Ethics and dissemination The RadComp trial has 
been approved by the institutional review boards of 
all participating sites. Recruitment began in February 
2016. Current version of the protocol is A3, dated 08 
strengths and limitations of this study
 ► The pragmatic and holistic approach reflects ‘re-
al-world’ clinical practice, identifies subgroups of 
patients who might benefit more from proton ther-
apy and helps patients and physicians understand 
and apply findings to their own lived experience.
 ► Engagement of patients and other essential stake-
holders in the design and conduct of large scale 
pragmatic randomised control trials of a promising, 
but expensive, medical technology will inform future 
efforts to conduct holistic, patient-centric and prag-
matic comparative effectiveness research as part of 
a learning healthcare system.
 ► Blinded, centralised adjudication of primary out-
comes applies consistent, relevant definitions of 
fatal and non-fatal events comprising the major 
cardiovascular endpoint to detect possible events 
and avoids the influence of investigator or patient 
ascertainment bias.
 ► The Radiotherapy Comparative Effectiveness 
Consortium may have the appearance of conflict of 
interest (COI) as it involves centres with proton ther-
apy capabilities. COI concerns are addressed by ran-
domised study design, blinded adjudication of primary 
outcome, accountability by the data safety monitoring 
board, and declaration, disclosure and management of 
COI.
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November 2018. Dissemination plans include presentations at scientific 
conferences, scientific publications, stakeholder engagement efforts 
and presentation to the public via lay media outlets.
trial registration number NCT02603341
IntroduCtIon
The Pragmatic Randomised Trial of Proton versus Photon 
Therapy for Patients with Non-Metastatic Breast Cancer: 
A Radiotherapy Comparative Effectiveness (RadComp) 
Consortium Trial is a large-scale, multicentre pragmatic 
randomised clinical trial following patients longitudinally 
for cardiovascular morbidity and mortality, health-related 
quality of life (HRQOL) and cancer control outcomes. 
We focus on radiotherapy for breast cancer requiring 
internal mammary nodal irradiation because: (1) regional 
node radiotherapy is an important component of cura-
tive treatment for high risk breast cancer; (2) the survival 
advantages of radiotherapy may be reduced by incidental 
radiation to the heart; (3) proton therapy, by reducing 
incidental radiation to the heart and other normal tissues, 
may lead to meaningful reductions in cardiac morbidity 
and mortality and improvements in HRQOL and (4) 
patients with breast cancer seek evidence on disease 
control, quality of life and cardiovascular outcomes after 
proton versus photon therapy to help make shared deci-
sions with their physicians about treatment options.
Our primary hypothesis is that proton therapy, as part 
of multimodality curative treatment for patients with 
non-metastatic breast cancer who have indications for 
regional nodal irradiation, reduces major cardiovascular 
events (MCEs) compared with photon therapy. MCEs are 
defined as myocardial infarction, coronary revascularisa-
tion, cardiovascular death or hospitalisation for unstable 
angina, heart failure, valvular disease, arrhythmia or 
pericardial disease. Photon therapy, delivered as either 
intensity-modulated radiotherapy or three-dimensional 
(3D) conformal radiotherapy, uses multiple X-ray beams 
to irradiate a tumour target but unavoidably deposits 
radiation in normal tissues beyond the target volume. In 
contrast, proton therapy directs a beam of protons (posi-
tively charged subatomic particles) at the target volume, 
where they deposit the bulk of their energy in the last few 
millimetres of their range.1 Proton radiation dose distri-
butions may appear superior to photon therapy, particu-
larly in the reduction of low and intermediate radiation 
dose to normal tissues like the heart and lungs.
However, both photon and proton therapy have physical 
and biological uncertainties that could impact important 
clinical outcomes. For example, investigators have noted 
uncertainties about the exact range of the proton therapy 
in tissue and its biological effects at the end of the range.2 
In addition, due to their distinct physical properties, 
there may be differences in the biological effect of proton 
therapy and photon therapy on normal tissues.
Thus, a broad range of stakeholders (patients, 
providers, manufacturers, researchers and policy-makers) 
have called for randomised evidence on the clinical 




This study is a superiority pragmatic randomised clinical 
trial in breast cancer to compare two external beam radi-
ation therapies: proton versus photon therapy. Treatment 
techniques represent current care standards and are easy 
to replicate. Study endpoints are assessed via self-report, 
medical record review, vital records database search and 
centralised adjudication. The primary outcome is assessed 
by an adjudication team of cardiologists who are blinded 
to treatment assignment.
Informed by the work of Sedrakyan, Luce, Ellenberg 
and Treweek,10–14 the conceptual framework for the 
trial (figure 1) addresses sources of variability that are 
unique to radiation devices, including facility and device 
characteristics.
The RadComp trial has in common a highly pragmatic 
approach in most Pragmatic Explanatory Continuum Indi-
cator Summary domains15 (table 1). We highlight three 
choices essential to maintaining internal and external 
validity: first, the trial is open label (both the researchers 
and participants know which treatment is administered); 
however, we conduct independent, centralised primary 
outcome adjudication of MCEs to protect against differ-
ential misclassification between treatment groups. 
Second, participant eligibility is minimally restricted, 
without exclusions for pre-existing comorbidities, and 
treatment is flexible in dosing and technique; however, 
we provide the best practice guidelines for radiotherapy 
delivery, consistent with prior pragmatic clinical trials of 
technologically complex treatments (based on consensus 
among RadComp centres).16 Third, treatment decisions 
are at the discretion of the local treating providers and 
patients; however, we will store radiotherapy treatment 
plans within the RadComp Radiorepository for retrospec-
tive research review.
overall aims
Aim 1 addresses the effectiveness of proton versus photon 
therapy in reducing MCEs. Aim 2 assesses the non-inferi-
ority of proton versus photon therapy in reducing risk of 
breast cancer local-regional recurrence and in reducing 
risk of any recurrence, defined as the first reported breast 
cancer recurrence of any type (local-regional or distant 
recurrence or cancer-specific mortality). Aim 3 considers 
the effectiveness of proton versus photon therapy in 
improving physical, mental and social HRQOL; specif-
ically, body image and function in breast cancer, and 
fatigue, anxiety, social roles, general HRQOL, side effects 
burden and satisfaction. Aim 4 focuses on development 
of predictive models to examine the associations of radia-
tion dose distributions and MCE and HRQOL to identify 
subgroups of patients most likely to benefit from proton 
or photon therapy.
M
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Figure 1 Conceptual framework for randomised pragmatic clinical trial of proton versus photon therapy for locally advanced 
breast: generating patient centric, real-word evidence.
Eligibility
Eligibility criteria are defined broadly to maximise gener-
alisability of results, striking a balance between pragma-
tism and treatment appropriateness (table 2). Rarely, 
patients will be ineligible if proton or photon therapy 
cannot be administered safely.
baseline assessments
Prior to randomisation, enrolled patients complete initial 
assessments that include a patient interview and medical 
record review to assess relevant prerandomisation covari-
ates. Additional data regarding patient contact and alter-
nate contacts information and baseline HRQOL are 
collected.
Interventions
Patients are randomly assigned to receive either photon 
or proton therapy. Participants are stratified by age (<65 
vs ≥65), cardiovascular risk (0–2 vs >2 risk factors), surgery 
(mastectomy vs lumpectomy) and laterality (left sided vs 
right sided) (figure 2). Bilateral patients are classified as 
left sided.
Proton therapy techniques may include passively scat-
tered or scanning technology. All patients receive breast/
chest wall and comprehensive nodal radiation therapy 
including internal mammary node treatment. Treatment 
planning guidelines are described in the protocol, avail-
able on request. A contouring atlas has been developed 
for guidance and is available at https://www. rtog. org/ 
CoreLab/ ContouringAtlases/ RADCOMPBreastAtlas. 
aspx. A novel aspect of this atlas is that it can be viewed in 
coronal, axial and sagittal planes by treating physicians.
radComp radiorepository
In a technology-based medical discipline like radia-
tion oncology, significant centre-to-centre variations 
exist in implementation of technologies.11 We draw a 
balance between allowing for local practice variation 
while promoting the best practice radiotherapy delivery 
across centres; this effort is crucial to conduct a valid, 
credible study, as well as to minimise the number of 
patients required and maximise the protection of partic-
ipants.17 18 The RadComp Radiorepository collects and 
stores three-dimensional radiation treatment plans for 
all patients through the data collection infrastructure 
provided by The Cancer Imaging Archive (TCIA)19 20 
to ensure efficiency of these processes for participating 
centres. Data are stored in TCIA with the approval of the 
National Cancer Institute (NCI), as a private collection 
M
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Table 1 Key elements of the RadComp pragmatic 
approach to study design
Domain
Typical explanatory 
RCT RadComp Pragmatic RCT
Blinding Open label Open label
Participant 
eligibility
Highly selected (avoid 
diluting effect)
Little selection beyond the 










Expert subspecialists at 
elite academic settings
Academic and community 
settings, real-world care
Follow-up Frequent research 
visits, more extensive 
than routine care
Annual research visits, tied 











Variable Independent, blinded, 
centralised primary 
outcome adjudication
Adherence Stringent for both 
patient and provider
Relaxed, usual care, best 
practice recommendations
Analysis Intention to treat Intention to treat
Relevance to 
practice
Indirect: trial design ≠ 
needs of stakeholders
Direct: trial design = 
needs of patients and 
stakeholders
HRQOL, health-related quality of life; MCE, major cardiovascular 
event; RadComp, Radiotherapy Comparative Effectiveness; RCT, 
randomised controlled trial; RT, radiation therapy.
Table 2 Summary of inclusion and exclusion criteria for the RadComp trial
Inclusion 
criteria
 ► Age ≥21 years.
 ► Females or males diagnosed with pathologically (histologically) proven invasive mammary carcinoma 
(ductal, lobular or other) of the breast who have undergone either mastectomy or lumpectomy/local excision 
with any type of axillary or internal mammary node chain surgery or sampling or who have had a local 
recurrence.
 ► Must be proceeding with breast/chest wall and nodal radiation therapy including internal mammary node 
treatment.
 ► Confirmation that participant’s health insurance or an alternative source will pay for the cost of proton or 
photon therapy treatment on the study.
Exclusion 
criteria
 ► Definitive clinical or radiological evidence of metastatic disease.
 ► Prior radiotherapy to the ipsilateral chest wall, breast or thorax.
 ► Scleroderma.
RadComp, Radiotherapy Comparative Effectiveness.
Figure 2 Study stratification schema.
and can be made publicly available at an appropriate time 
following the completion of the trial.
Centralised adjudication of primary outcomes
The RadComp Clinical Events Centre (CEC) will conduct 
centralised adjudication of clinical events related to the 
primary outcomes of MCEs. The objectives of the CEC 
are: (1) to apply consistent, simple, relevant definitions of 
the fatal and non-fatal cardiovascular events comprising 
the MCE endpoint to detect possible events and to avoid 
the influence of investigator or patient ascertainment bias 
and (2) to conduct adjudication blinded to treatment 
assignment to protect against differential misclassification 
events. The goal of centralised adjudication of primary 
outcomes is to increase confidence in the validity of 
our findings.21–23 Leveraging the best practice adjudi-
cation procedures from the National Lung Screening 
Trial24 and prior work at the University of Pennsylvania 
in managing large, complex clinical event adjudication 
programmes,25 26 the CEC employs key processes to 
define, identify, track, investigate and determine whether 
a primary event has occurred. The RadComp adjudica-
tion manual is available on request.
outcomes, patient characteristics, and facility and device 
characteristics
As shown in the conceptual framework, study measures 
include primary outcomes (MCE), secondary outcomes, 
baseline stratification factors, patient characteristics and 
facility characteristics.
Major cardiovascular events
The primary outcome is MCE, defined as myocardial 
infarction, coronary revascularisation, cardiovascular 
death or hospitalisation for unstable angina, heart 
failure, valvular disease, arrhythmia, or pericardial 
disease.
M
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Local-regional recurrence and any recurrence
The primary cancer control outcome is local-regional 
recurrence, defined as the local recurrence as a first 
event.27–29 We will also evaluate any recurrence, defined 
as the first reported breast cancer recurrence of any type 
(local-regional or distant recurrence or cancer-specific 
mortality).
Baseline cardiovascular disease
Assessed at baseline, elevated risk of cardiovascular 
disease is defined by a history of coronary artery disease 
or myocardial infarction, atrial fibrillation/flutter, hyper-
tension, diabetes, renal failure, hyperlipidaemia, heart 
failure, cardiomyopathy, smoking (current/former), 
prior contralateral left breast or chest wall radiation, prior 
anthracycline therapy or prior trastuzumab therapy. We 
choose this approach as both valid (based on the Fram-
ingham risk score) and consistent with our pragmatic 
framework, acknowledging that some cardiovascular risk 
stratification schemes include laboratory or echocardio-
graphic assessment.30 Other cardiovascular risk factors 
(including family history) will be assessed but will not 
contribute to the definition of cardiovascular risk factors 
for the purposes of stratification.
Patient characteristics
We will collect demographic information including 
gender, race, ethnicity, marital status, educational attain-
ment, insurance, household income, comorbidity assess-
ment and disease severity, leveraging the Patient-Reported 
Outcomes Measurement Information System (PROMIS) 
sociodemographic and comorbidity questionnaire.31
Facility/device characteristics and radiation dose distribution
We will investigate the relationship between proton and 
photon dose distribution metrics and differences in MCE 
and HRQOL in order to identify subgroups of patients 
that might benefit from proton or photon therapy. To 
facilitate this analysis, we will record patient-level radia-
tion dose distributions and treatment delivery parameters, 
facility and device radiation technical characteristics, and 
any evolution of radiation techniques over time through 
the RadComp Radiorepository. We also will conduct 
centralised contouring of organs at risk, including the 
heart and its substructures (left anterior descending 
artery, left and right atria, left and right ventricles, left 
main, left circumflex and the right coronary artery, 
lungs, oesophagus and thyroid). Centralised contouring 
is important in any radiotherapy trial but is particularly 
pertinent to a pragmatic trial in which the local norms 
of anatomic delineation for radiation treatment planning 
vary widely.32 33 While patients will be treated according 
to anatomic delineation of local providers, centralised 
contouring will be conducted by trained staff at the 
RadComp Coordinating Centre and the results stored 
in the Radiorepository. Participating sites must submit 
a facility questionnaire, complete a physics plan review 
and demonstrate successful digital data submission to the 
Radiorepository prior to study initiation.
hrQoL instruments
The HRQOL instruments and outcomes chosen for the 
proposed trials are hypothesis driven, validated, reliable 
and have been shown to be meaningful to patients.34–37 
Each instrument is described below. The estimated 
patient response burden to complete these instruments is 
approximately 30 min.
Functional Assessment of Cancer Therapy-Breast
The Functional Assessment of Cancer Therapy-Breast 
(FACT-B) measures general and breast cancer-specific 
HRQOL.38 It has multiple subscales, three of which are 
combined to form a Trial Outcome Index that is useful 
for clinical trials. It also has a four-item arm mobility 
subscale39 40 and two items to measure pain and swelling.
BREAST-Q
The BREAST-Q was designed to evaluate outcomes among 
women undergoing different types of breast surgery.41 A 
five-item subscale to assess adverse effects of radiotherapy 
will be used in this trial.
Satisfaction with breast cosmetic outcomes
This six-item scale was developed to provide a brief assess-
ment of patient-reported cosmetic outcomes after breast 
cancer treatment.42
PROMIS fatigue
The four-item fatigue short form combines items on 
fatigue experience and interference derived from the 
Functional Assessment of Chronic Illness Therapy 
(FACIT) system and PROMIS.31 43–45 It has been used 
extensively in oncology trials and is responsive to change 
after radiation therapy.
PROMIS anxiety
Anxiety is a common concern among patients with 
cancer34 and is especially relevant for the RadComp trials. 
The PROMIS 4-item short form for Anxiety was devel-
oped based on content and psychometric measurement 
precision.46
PROMIS social roles
Social function has historically been a relatively neglected 
domain due to the lack of measures for clinical popu-
lations. A four-item PROMIS short form will be used in 
this trial, derived from the validated a 35-item measure of 
ability to participate in social roles and activities.47
This side effects short form will solicit experience, 
shortness of breath and chest pain. Items were selected 
from the NCI’s Patient-Reported Outcomes version of 
the Common Terminology Criteria for Adverse Events 
(PRO-CTCAE) system, which was developed to collect 
patient reports of symptoms they are experiencing while 
undergoing treatment, for the purpose of enhancing 
adverse event (AE) reporting (http:// healthcaredelivery. 
M
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cancer. gov/ pro- ctcae/) or were written for this trial using 
the PRO-CTCAE format. A single item from the FACT-B 
will also be used to measure the overall burden of side 
effects (‘I am bothered by side effects of treatment: not at 
all, a little bit, somewhat, quite a bit, very much’), as used 
in prior cancer studies.48–50
Functional Assessment of Chronic Illness Therapy-Treatment 
Satisfaction-General
The FACIT system includes an eight-item measure of 
general satisfaction with treatment, developed and vali-
dated with patients with cancer and HIV/AIDS.51 Six of 
the eight items will be used in this trial.
Financial burden
In discussion with the stakeholder advisory committee, we 
included an item to assess overall financial burden. This 
item is part of the European Organization for Research 
and Treatment of Cancer QLQ-C30 instrument: ‘Has 
your physical condition or medical treatment caused you 
financial difficulties?’ (not at all, a little bit, quite a bit, 
very much).52
Productivity
This single item has been developed to assess the extent 
that a patient was able to resume normal activities. It is 
rated on a 0%–100% scale.53
EuroQOL-5D
The EuroQOL-5D is a standardised two-part, self-admin-
istered instrument for direct and indirect assessment of 
health state utilities; it is cognitively simple, takes only a 
few minutes to complete and yields a utilities index value 
for health status.54
recruitment
All patients will be recruited in clinic settings between 
the time of presentation with breast cancer and prior to 
start of radiation therapy. Radiation oncologists at each 
recruiting site will assess willingness for their patients to 
be enrolled.
RadComp recruiting sites have been selected to repre-
sent a broad range of geographic locations and prac-
tice settings in the USA, including large teaching and 
non-teaching treatment centres and smaller community 
facilities. The site selection process for RadComp included 
consideration of volume of patients with breast cancer, 
treatment practices and presence of buy-in from clinical 
leaders. Over 95% of existing proton therapy treatment 
centres in the USA are participating in the trial.
AE monitoring
At each contact with the subject, including the pretreat-
ment assessment, the investigator seeks information 
on AEs by specific questioning and, as appropriate, by 
examination. AEs will be recorded by clinicians using 
the National Cancer Institute Common Toxicity Criteria 
for Adverse Events (CTCAE) V.4.0, a comprehensive, 
multimodality grading system for reporting the acute and 
late effects of cancer treatment.55
data analysis and management
Analyses for all endpoints will follow the intention-to-treat 
principle. As-treated analyses will be conducted for MCEs 
and other safety endpoints secondarily. The primary anal-
ysis will be a comparison of time to MCE between treatment 
arms. Log-rank tests will be used to compare the time to 
MCE between treatment arms; Kaplan-Meier plots will be 
used to graphically depict time to MCE by treatment arm. 
The main subgroups assessed for heterogeneity of treat-
ment effects (HTE) within Cox models will be the strat-
ification factors as defined in the schema. In secondary 
analyses, we will assess the influence of patient character-
istics (gender, race, ethnicity, marital status, education, 
health literacy, income, insurance status, comorbidities 
and disease severity) and device and facility characteris-
tics (radiation dose distribution, facility and device radi-
ation technical characteristics, change in technique over 
time). To account for the presence of competing risks, 
we also will conduct secondary analyses of the cumula-
tive incidence of MCE using non-parametric cumulative 
incidence functions. We will use the Fine-Gray semipara-
metric model for subdistribution hazards to estimate the 
effects of stratification factors and other covariates.
Initial evaluation of HTE will be made by analysis of 
interactions between treatment and patient-level and 
facility/device covariates using a Cox regression model 
with the primary outcome (MCE) as the dependent vari-
able. Treatment effects within subgroups, such as ethnicity 
and race, will be conducted if any treatment–covariate 
interactions are at least suggestive (p<0.20) and sample 
sizes and numbers of events within these subgroups are 
sufficient for analysis. Due to the exploratory nature of 
these analyses and the expected limited sample size in 
each subgroup, no adjustments for multiple compari-
sons will be made. These analyses will follow the primary 
comparisons as specified for MCE.
Power and sample size
Our primary hypothesis is that treatment with proton 
therapy as compared with photon therapy will reduce the 
rate of MCEs.
The study will randomise 1278 patients to photon 
therapy versus proton therapy for treatment of breast 
cancer. The 10-year estimate of the proportion of patients 
with breast cancer with MCEs in the photon arm is esti-
mated to be 6.3% based on study team analyses of data 
from the Surveillance Epidemiological End Results data-
base (available on request from the authors). Assuming 
a 45% relative reduction of MCEs using proton therapy, 
resulting in an MCE rate of 3.5% for the proton arm, 
this sample will provide 80% power to detect this differ-
ence between the two arms using a log-rank test with a 
one-sided alpha of 0.05. A sample size of 1278 will allow 
sufficient power with a loss to follow-up rate of 13%.
M
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The planned sample size will also provide sufficient 
power for testing hypotheses related to our secondary 
outcomes. An underlying assumption is that proton 
therapy will not negatively impact cancer control 
outcomes. This assumption is biologically plausible given 
similar radiation doses and biological effects of protons 
and photons on tumour bed targets; yet, clinical evidence 
is scarce. We plan to evaluate local-regional relapse, the 
primary cancer control outcome of interest for radiation, 
using a non-inferiority approach. Non-inferiority margins 
were evaluated based on prior studies showing improve-
ments in local-regional relapse rates with photon therapy, 
relative to no radiation.28 29 With a sample size of 1278 
patients, there is 80% power for a 5-year non-inferiority 
margin not higher than 3.8% for local-regional recur-
rence assuming local-regional recurrence in the photon 
arm of 5% at 5 years using a log-rank test with a one-sided 
alpha of 0.025. We will examine cancer-specific and 
overall survival according to methods described above for 
time-to-event analyses.
For HRQOL outcomes, effect sizes were estimated as 
the expected difference between groups at the 6-month 
assessment. A correlation of 0.40–0.60 between repeated 
measures was assumed, based on data from previous longi-
tudinal studies of HRQOL and satisfaction in patients with 
cancer.56–58 An effect size of 0.33 corresponds to a clini-
cally important difference in HRQOL outcomes.59 60 The 
proposed sample sizes in each treatment arm (n=650) will 
be sufficient to detect an effect size of 0.33 under various 
scenarios. For example, even with a correlation as low as 
0.40, 174 patients per treatment arm will provide power 
of 80% at a two-sided significance level of 0.05. Adjusting 
for multiple primary endpoints in the breast cancer trial, 
330 patients per treatment arm will provide power of 
90% at a two-sided significance level of 0.01. There will 
be adequate statistical power even with assuming 15% 
drop-out.
study monitoring
The Radiation Therapy Oncology Group Foundation 
data monitoring committee (DMC) will review the study 
twice a year with respect to patient accrual and morbidity, 
and at any other times on an ‘as needed’ basis. The 
review of the study will include, but not be limited to, the 
following items: accrual, baseline demographic charac-
teristics, withdrawal rates, toxicity data, protocol compli-
ance, treatment arm-specific data including radiation 
dose, toxicity and compliance, HRQOL questionnaire 
compliance, interim analyses of AEs and safety results 
and outcome analyses results. Data by treatment arm will 
be seen only by the DMC, which will assess the integrity 
of the accruing data and compare selected measures 
between treatment arms that may affect study validity or 
raise potential ethical concerns regarding safety.
Patient and public involvement
Since 2009, leaders of the RadComp Consortium have 
convened or participated in workgroups of patients, 
clinicians, methodologists, cancer researchers, payers, 
product developers, vendors and government represen-
tatives to explore the feasibility of alternative efficacy and 
effectiveness study designs and to build momentum for 
comparative studies of proton and photon therapy (These 
efforts resulted in the currently accruing NCI-sponsored 
efficacy PARTIQoL trial).61–63 In 2014, RadComp inves-
tigators called for randomised trial evidence generation 
for proton therapy in breast and lung cancer64 and the 
current multi-institutional RadComp Consortium of 22 
proton/photon centres agreed to seek Patient-Centered 
Outcomes Research Institute funding for a pragmatic 
randomised clinical trial. In June 2014, in partnership 
with the NCI’s Radiation Research Branch, the Consor-
tium hosted a stakeholder engagement meeting on the 
NCI campus, in which we gained important insights on 
the formulation of the research questions, study designs, 
study implementation plans and other key characteristics 
of comparative effectiveness research.3
We learnt from stakeholders that one essential chal-
lenge in conducting randomised trials of proton therapy 
is restrictive insurance coverage for proton therapy, partic-
ularly for breast cancer.65 While Medicare typically covers 
proton therapy for breast cancer indications, commercial 
insurers are more restrictive; however, reasonable clinical 
rationale supports coverage of radiation modalities such as 
intensity-modulated photon therapy or proton therapy for 
patients with breast cancer who require internal mammary 
node treatment (that is, patients with breast cancer clin-
ically eligible for RadComp). Restrictive commercial 
coverage policies for proton therapy may impact the pace 
of enrolment to RadComp and the generalizability of the 
results. Therefore, RadComp engages with stakeholders to 
develop potential solutions to support for trial participation 
for eligible and interested patients.
The Stakeholder Advisory Committee and the larger 
stakeholder group have and will continue to participate 
in stakeholder deliberations. The Stakeholder Advisory 
Committee provides their insight on: (1) the creation of 
strategies to recruit and retain all patient populations, 
(2) developing study talking points in plain language 
to overcome patient confusion or fear of the concept 
of equipoise/uncertainty among treatment options, (3) 
translating study findings and (4) mechanisms for the 
broad dissemination and implementation of the best 
practices.
Ethics and dissemination
Of currently approved sites, nine have designated the 
University of Pennsylvania IRB as the IRB of record. 
Recruitment began in February 2016 and will continue 
through the end of 2021. Changes to the protocol will 
be communicated via teleconferences and memos to all 
sites with an expected date of implementation. Training 
on the changes will be documented.
Protected health information is only shared with 
research team members as required for completion of 
designated study tasks. Patient contact information for 
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follow-up is only transmitted to the coordinating centre 
via secure network servers. All team members needing 
access to identifiable study data will be required to submit 
appropriate trainings and roster forms to request access. 
Logs of dates and times of database accessed will be kept, 
including an audit trail of data changes.
ConCLusIon
The RadComp trial will evaluate outcomes after proton or 
photon therapy for patients with breast cancer through a 
real-world, patient-centred pragmatic randomised clinical 
trial. RadComp’s goal is to generate new knowledge about 
the relative effects of these approaches while ensuring that 
treatment reflects high-quality routine clinical practice, 
identifies subgroups of patients that might benefit more 
from either treatment, and helps patients and physicians 
understand and apply our findings to their own experi-
ence. Patients with breast cancer considering photon or 
proton therapy make treatment decisions in the context of 
extremely sparse comparative effectiveness evidence, and 
then may live for years with clinically burdensome treat-
ment-related morbidity that affects their quality of life and 
engagement in activities of living. The RadComp trial results 
will be directly relevant to many thousands of patients who 
confront these difficult treatment decisions every day.
Author affiliations
1Department of Radiation Oncology, University of Pennsylvania Perelman School of 
Medicine, Philadelphia, Pennsylvania, USA
2American College of Radiology, Philadelphia, Pennsylvania, USA
3Department of Radiation Oncology, University of Maryland School of Medicine, 
Baltimore, Maryland, USA
4Division of Cancer Epidemiology and Genetics, National Cancer Institute, National 
Institutes of Health, Bethesda, Maryland, USA
5Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New 
York city, New York, USA
6Department of Radiation Oncology, Washington University in St. Louis, St. Louis, 
Missouri, USA
7Mayo Clinic Minnesota, Rochester, Minnesota, USA
8Department of Biostatistics, Epidemiology and Informatics, University of 
Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
9Department of Radiation Oncology, University of Washington School of Medicine, 
Seattle, Washington, USA
10Department of Medical Social Sciences, Northwestern University, Evanston, 
Illinois, USA
11Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New 
Brunswick, New Jersey, USA
12Department of Radiation Oncology, Massachusetts General Hospital, Harvard 
Medical School, Boston, Massachusetts, USA
13Northwestern Medicine Chicago Proton Center, Warrenville, Illinois, USA
14Cardio-Oncology Program, Division of Cardiovascular Medicine, University of 
Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
15PHSR, University of Maryland School of Pharmacy, Baltimore, Maryland, USA
16Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA
17Department of Biomedical Informatics, University of Arkansas for Medical 
Sciences, Little Rock, Arkansas, USA
18Provision Proton Therapy Center, Knoxville, Tennessee, USA
twitter @theRadCompStudy
Acknowledgements The authors thank Tanya Alexander, Carole Baas, Joanne 
Buzaglo, Andrea Denicoff, Ashley Feriozzi, Dana Goodlett, Carolyn Hencek, Anna 
Hung, Holly Massett and Kim Wright for their contributions to the study.
Collaborators RadComp Consortium: Massachusetts General Hospital: David 
Gierga, RBJ, SMM, Harald Paganetti, Daniel Soto, AZT; Mayo Clinic, Arizona: Aman 
Anand, Michelle Halyard, Lisa A. McGee; Mayo Clinic, Rochester: Kimberly Corbin, 
RWM, Nicholas Remmes, Elizabeth Yan; MDAnderson Cancer Center: Elizabeth S. 
Bloom, Karen E. Hoffman, Falk Poenisch, Benjamin Smith, Xiaorong Ronald Zhu; 
Memorial Sloan Kettering Cancer LZB, OC, John Cuaron, Daphna Gelblum, Erin 
Gillespie, Linda Hong, AJK, Beryl McCormick, Borys Mychalczak, Preeti Parhar, 
SNP, Paul Romesser, KDS, Anne Marie Shepherd; Miami Cancer Institute: Jaafar 
Bennouna, Marcio A. Fagundes, Alonso Gutierrez, Jennifer Yu: Northwestern 
University: David Cella, CMK, Stephen Mihalcik, MP; Michael Stutz; Orlando Health: 
Tomas Dvorak, Omar Zeidan; Pinnacle Health: Eugene Fourkal, David C. Weksberg; 
ProCure NJ: Dennis Mah, Henry Tsai; ProCure Oklahoma: Jeffrey Campbell, Kiran 
Prabhu, Trevor Twyford; Provision Proton Center: Allen Meek, Niek Schreuder, 
J. Ben Wilkinson; Rutgers Cancer Institute of New Jersey: Sharad Goyal, BGH, 
Rihan Millevoi, Nisha Ohri; Texas Center for Proton Therapy: Chang Chang, Jared 
Sturgeon; University of Arkansas Medical School: William Bennett, FP, Lawrence 
Tarbox; University of California, San Diego: Jyoti Mayadev,Vitali Moiseenko, 
Dominique Rash, James Urbanic, Catheryn Yashar; University of Florida Proton 
Therapy Institute: Julie A. Bradley, Xiaoying Liang, Nancy Mendenhall, Michael 
Rutenberg: University Hospitals: Chee-Wai Cheng, Janice Lyons: University of 
Maryland: Katja Langen, MVM, Elizabeth Nichols; Perelman School of Medicine, 
University of Pennsylvania: Abigail Berman, Steven Feigenberg, GMF, James Kolker, 
Lilie Lin, Suneel Nagda, Ann Marie Siegal, Neil Taunk; University of Washington: 
LMF, Tony Wong; Washington University in St. Louis: Sasa Mutic, William Straube, 
Imran Zoberi; William Beaumont Hospital: Peter Chen, Xuanfeng Ding; Willis 
Knighton: Phuong Daniella Dang, Sanford Katz, Lane R. Rosen, Terry Wu.
Contributors JEB, SP, KB, ABdG, WB, CC, BK, CL, H-ML, CDM, MP, FWP, SMM and 
OC each made substantial contributions to the conception or design of the study 
protocol. JEB conceived the overall study and wrote the first draft of the protocol 
and with HL, the first draft of this manuscript. KB, CDB, ABdG, WB, CC, EAH, H-ML, 
CDM, MP, FWP, SMM and OC provided critical input regarding the design of the 
study intervention, study outcomes and study procedures; JEB, SP and SE designed 
the data analysis and management plan. JEB, HL, SP, KB, WB, SE, H-ML, CDM, 
MP, SMM and OC revised the protocol critically for important intellectual content 
and approved the final version to be published. LZB, L-MF, GMF, BGH, AJK, RBJ, 
CK, MVM, RWM, SN, SNP, KS, AGT, JBW, SMM and OC and RadComp Consortium 
all contributed to the data collection. JEB, HL, SP, SE, SMM and OC agreed to be 
accountable for all aspects of the work in ensuring that questions related to the 
accuracy or integrity of any part of the work are appropriately investigated and 
resolved.
Funding This work was funded through a Patient-Centered Outcomes Research 
Institute (PCORI) Award (PCS-1403-12804).
disclaimer The views, statements and opinions presented in this work are solely 
the responsibility of the author(s) and do not necessarily represent the views of the 
PCORI, its Board of Governors or Methodology Committee.
Competing interests JEB, SE, CDM and BK report grants from PCORI, during the 
conduct of the study. SNP, WB, L-MF, BGH, CK, MVM, RWM, FWP, SMM and OC 
report grants from University of Pennsylvania subcontracts as study investigator, 
during the conduct of the study.
Patient consent for publication Not required.
Ethics approval University of Pennsylvania Perelman School of Medicine 
Institutional Review Board (IRB) and the IRBs or Research Ethics Boards (REBs) of 
23 participating US institutions.
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
rEFErEnCEs
 1. Ollendorf DA, Colby J. Proton beam therapy: ICER final evidence 
report Washington State Health Technology Assessment Program; 
2014. http://www. hca. wa. gov/ hta/ Documents
 2. Urie M, Goitein M, Wagner M. Compensating for heterogeneities in 
proton radiation therapy. Phys Med Biol 1984;29:553–66.
M





ber 18, 2019 at W




pen: first published as 10.1136/bmjopen-2018-025556 on 15 October 2019. Downloaded from 
9Bekelman JE, et al. BMJ Open 2019;9:e025556. doi:10.1136/bmjopen-2018-025556
Open access
 3. National Academies. Initial national priorities for comparative 
effectiveness research: report brief, 2009. Available: https://www. 
nap. edu/ read/ 12648/ chapter/1 [Accessed 5 Sep 2017].
 4. Terasawa T, Dvorak T, Ip S, et al. Systematic review: charged-particle 
radiation therapy for cancer. Ann Intern Med 2009;151:556–65.
 5. Moya del Pina B, NCI Cancer Bulliten. Proton therapy for cancer: 
a new technology brief, 2009. Available: http://www. cancer. gov/ 
ncicancerbulletin/ 090809/ page8 [Accessed 12 Nov 2009].
 6. Centers for Medicare and Medicaid Services. Potential national 
coverage decision topics, 2008. Available: <http://www. cms. hhs. gov/ 
mcd/ ncpc_ view_ document. asp? id= 19>
 7. Brada M, De Ruysscher D, Pijls-Johannesma M. Evidence for proton 
therapy. J Clin Oncol 2008.
 8. Lodge M, Pijls-Johannesma M, Stirk L, et al. A systematic literature 
review of the clinical and cost-effectiveness of hadron therapy in 
cancer. Radiother Oncol 2007;83:110–22.
 9. Sheehan M, Timlin C, Peach K, et al. Position statement on ethics, 
equipoise and research on charged particle radiation therapy. J Med 
Ethics 2014;40:572–5.
 10. Ellenberg S. Oversight of pragmatic clinical trials. National cancer 
policy forum workshop. Available: http:// iom. edu/ Activities/ Disease/ 
NCPF/ 2014- FEB- 24/ Day% 202/ Session% 205/ 28- Ellenberg- Video. 
aspx
 11. Sedrakyan A, Marinac-Dabic D, Normand S-LT, et al. A framework for 
evidence evaluation and methodological issues in implantable device 
studies. Med Care 2010;48(6 Suppl):S121–S128.
 12. Treweek S, Zwarenstein M. Making trials matter: pragmatic and 
explanatory trials and the problem of applicability. Trials 2009;10:37.
 13. Luce BR, Kramer JM, Goodman SN, et al. Rethinking randomized 
clinical trials for comparative effectiveness research: the need for 
transformational change. Ann Intern Med 2009;151:206–9.
 14. Ellenberg SS, Foulkes MA. The utility of large, simple trials in the 
evaluation of AIDS treatment strategies. Stat Med 1994;13:405–15.
 15. Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic-
explanatory continuum indicator summary (Precis): a tool to help trial 
designers. J Clin Epidemiol 2009;62:464–75.
 16. Prospective multicenter imaging study for evaluation of chest pain 
(promise), 2014. Available: http:// projectreporter. nih. gov/ project_ 
info_ description. cfm? aid= 7940886& icde= 5559996 [Accessed 5 Mar 
2014].
 17. Bekelman J, Deye J, Vikram B. 2011. Redesigning Radiotherapy 
Quality Assurance: Opportunities to Develop an Efficient, Evidence-
Based System to Support Clinical Trials.
 18. Pettersen MN, Aird E, Olsen DR. Quality assurance of dosimetry and 
the impact on sample size in randomized clinical trials. Radiother 
Oncol 2008;86:195–9.
 19. Clark K, Vendt B, Smith K, et al. The cancer imaging Archive (TCIA): 
maintaining and operating a public information Repository. J Digit 
Imaging 2013;26:1045–57.
 20. Kalpathy-Cramer J, Freymann JB, Kirby JS, et al. Quantitative 
imaging network: data sharing and competitive AlgorithmValidation 
Leveraging the cancer imaging Archive. Transl Oncol 2014;7:147–52.
 21. Granger CB, Vogel V, Cummings SR, et al. Do we need to adjudicate 
major clinical events? Clin Trials 2008;5:56–60.
 22. Bolland MJ, Barber A, Doughty RN, et al. Differences between self-
reported and verified adverse cardiovascular events in a randomised 
clinical trial. BMJ Open 2013;3:e002334.
 23. Dechartres A, Boutron I, Roy C, et al. Inadequate planning 
and reporting of adjudication committees in clinical trials: 
recommendation proposal. J Clin Epidemiol 2009;62:695–702.
 24. Marcus PM, Gareen IF, Miller AB, et al. The National lung screening 
trial's endpoint verification process: determining the cause of death. 
Contemp Clin Trials 2011;32:834–40.
 25. Feldman HI, Appel LJ, Chertow GM, et al. The chronic renal 
insufficiency cohort (CRIC) study: design and methods. J Am Soc 
Nephrol 2003;14(7 Suppl 2):148S–53.
 26. Bild DE, Bluemke DA, Burke GL, et al. Multi-Ethnic study 
of atherosclerosis: objectives and design. Am J Epidemiol 
2002;156:871–81.
 27. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of 
differences in the extent of surgery for early breast cancer on local 
recurrence and 15-year survival: an overview of the randomised 
trials. Lancet 2005;366:2087–106.
 28. Darby S, McGale P, Correa C, et al. Effect of radiotherapy after 
breast-conserving surgery on 10-year recurrence and 15-year breast 
cancer death: meta-analysis of individual patient data for 10,801 
women in 17 randomised trials. Lancet 2011;378:1707–16.
 29. McGale P, Taylor C, Correa C, et al. Effect of radiotherapy after 
mastectomy and axillary surgery on 10-year recurrence and 20-year 
breast cancer mortality: meta-analysis of individual patient data for 
8135 women in 22 randomised trials. Lancet 2014;383:2127–35.
 30. D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular 
risk profile for use in primary care: the Framingham heart study. 
Circulation 2008;117:743–53.
 31. Cella D, Riley W, Stone A, et al. The patient-reported outcomes 
measurement information system (PROMIS) developed and tested 
its first wave of adult self-reported health outcome item banks: 
2005–2008. J Clin Epidemiol 2010;63:1179–94.
 32. Li XA, Tai A, Arthur DW, et al. Variability of target and normal 
structure delineation for breast cancer radiotherapy: an RTOG multi-
institutional and multiobserver study. Int J Radiat Oncol Biol Phys 
2009;73:944–51.
 33. Spoelstra FOB, Senan S, Le Péchoux C, et al. Variations in target 
volume definition for postoperative radiotherapy in stage III Non–
Small-Cell lung cancer: analysis of an international contouring study. 
Int J Radiat Oncol Biol Phys 2010;76:1106–13.
 34. Reeve BB, Mitchell SA, Dueck AC, et al. Recommended patient-
reported core set of symptoms to measure in adult cancer treatment 
trials. J Natl Cancer Inst 2014;106.
 35. Basch E, Abernethy AP, Mullins CD, et al. Recommendations 
for incorporating patient-reported outcomes into clinical 
comparative effectiveness research in adult oncology. J Clin Oncol 
2012;30:4249–55.
 36. DeWalt DA, Rothrock N, Yount S, et al. Evaluation of item candidates: 
the PROMIS qualitative item review. Med Care 2007;45(5 Suppl 
1):S12–21.
 37. Aaronson N, Alonso J, Burnam A, et al. Assessing health status and 
quality-of-life instruments: attributes and review criteria. Qual Life 
Res 2002;11:193–205.
 38. Brady MJ, Cella DF, Mo F, et al. Reliability and validity of the 
functional assessment of cancer Therapy-Breast quality-of-life 
instrument. J Clin Oncol 1997;15:974–86.
 39. Coster S, Poole K, Fallowfield LJ. The validation of a quality of life 
scale to assess the impact of arm morbidity in breast cancer patients 
post-operatively. Breast Cancer Res Treat 2001;68:273–82.
 40. Fleissig A, Fallowfield LJ, Langridge CI, et al. Post-Operative arm 
morbidity and quality of life. Results of the ALMANAC randomised 
trial comparing sentinel node biopsy with standard axillary treatment 
in the management of patients with early breast cancer. Breast 
Cancer Res Treat 2006;95:279–93.
 41. Pusic AL, Klassen AF, Scott AM, et al. Development of a new patient-
reported outcome measure for breast surgery: the BREAST-Q. Plast 
Reconstr Surg 2009;124:345–53.
 42. Jagsi R, Li Y, Morrow M, et al. Patient-Reported quality of life and 
satisfaction with cosmetic outcomes after breast conservation 
and mastectomy with and without reconstruction. Ann Surg 
2015;261:1198–206.
 43. Garcia SF, Cella D, Clauser SB, et al. Standardizing patient-reported 
outcomes assessment in cancer clinical trials: a patient-reported 
outcomes measurement information system initiative. JCO 
2007;25:5106–12.
 44. Butt Z, Lai J-shei, Rao D, et al. Measurement of fatigue in cancer, 
stroke, and HIV using the functional assessment of chronic illness 
therapy — fatigue (FACIT-F) scale. J Psychosom Res 2013;74:64–8.
 45. Cella D, Lai J-S, Stone A. Self-reported fatigue: one dimension or 
more? Lessons from the Functional Assessment of Chronic Illness 
Therapy--Fatigue (FACIT-F) questionnaire. Support Care Cancer 
2011;19:1441–50.
 46. Pilkonis PA, Choi SW, Reise SP, et al. Item banks for measuring 
emotional distress from the patient-reported outcomes measurement 
information system (PROMIS®): depression, anxiety, and anger. 
Assessment 2011;18:263–83.
 47. Hahn EA, DeWalt DA, Bode RK, et al. New English and Spanish 
social health measures will facilitate evaluating health determinants. 
Health Psychol 2014;33:490–9.
 48. Cella DF, Patel JD. Improving health-related quality of life in non-
small-cell lung cancer with current treatment options. Clin Lung 
Cancer 2008;9:206–12.
 49. Cella D, Escudier B, Rini B, et al. Patient-Reported outcomes for 
axitinib vs sorafenib in metastatic renal cell carcinoma: phase III 
(axis) trial. Br J Cancer 2013;108:1571–8.
 50. Österborg A, Brandberg Y, Molostova V, et al. Randomized, double-
blind, placebo-controlled trial of recombinant human erythropoietin, 
epoetin beta, in hematologic malignancies. JCO 2002;20:2486–94.
 51. Peipert JD, Beaumont JL, Bode R, et al. Development and 
validation of the functional assessment of chronic illness therapy 
treatment satisfaction (FACIT Ts) measures. Quality of Life Research 
2014;23:815–24.
 52. Aaronson NK, Ahmedzai S, Bergman B, et al. The European 
organization for research and treatment of cancer QLQ-C30: a 
quality-of-life instrument for use in international clinical trials in 
oncology. J Natl Cancer Inst 1993;85:365–76.
M





ber 18, 2019 at W




pen: first published as 10.1136/bmjopen-2018-025556 on 15 October 2019. Downloaded from 
10 Bekelman JE, et al. BMJ Open 2019;9:e025556. doi:10.1136/bmjopen-2018-025556
Open access 
 53. Kornblith AB, Huang HQ, Walker JL, et al. Quality of life of patients with 
endometrial cancer undergoing laparoscopic International Federation 
of gynecology and obstetrics staging compared with laparotomy: a 
gynecologic Oncology Group study. JCO 2009;27:5337–42.
 54. Pickard AS, Wilke CT, Lin H-W, et al. Health utilities using the EQ-5D 
in studies of cancer. Pharmacoeconomics 2007;25:365–84.
 55. NIH. Cancer therapy evaluation program. Available: http:// ctep. 
cancer. gov
 56. Hahn EA, Glendenning GA, Sorensen MV, et al. Quality of life in 
patients with newly diagnosed chronic phase chronic myeloid 
leukemia on imatinib versus interferon alfa plus low-dose cytarabine: 
results from the iris study. JCO 2003;21:2138–46.
 57. Cella D, Hahn E, Webster K, et al. The FACIT treatment satisfaction 
measurement system. Quality of Life Research 2003;12.
 58. Fairclough D. Design and analysis of quality of life studies in clinical 
trials. 2nd ed. Boca Raton, FL: Chapman & Hall/CRC, 2010.
 59. Webster K, Cella D, Yost K. The functional assessment of 
chronic illness therapy (FACIT) measurement system: properties, 
applications, and interpretation. Health Qual Life Outcomes 
2003;1:79.
 60. Yost KJ, Eton DT. Combining distribution- and anchor-based 
approaches to determine minimally important differences: the FACIT 
experience. Eval Health Prof 2005;28:172–91.
 61. Proposed study of proton beam and intensity modulated radiation 
therapy (IMRT) in the treatment of prostate cancer, agency for 
healthcare research and quality. Rockville, MD; 2008.
 62. Comparative effectiveness of proton therapy and IMRT. Philadelphia, 
PA University of Pennsylvania; 2008.
 63. Comparative effectiveness of proton beam versus intensity 
modulated radiation therapy for treatment of early stage prostate 
cancer. Baltimore, MD Maryland room, world trade Center; 2009.
 64. Bekelman JE, Hahn SM. Reference pricing with evidence 
development: a way forward for proton therapy. J Clin Oncol 
2014;32:1540–2.
 65. Bekelman JE, Denicoff A, Buchsbaum J. Randomized trials of proton 
therapy: why they are at risk, proposed solutions, and implications 
for evaluating advanced technologies to diagnose and treat cancer. J 
Clin Oncol 2018;36:2461–4.
M





ber 18, 2019 at W




pen: first published as 10.1136/bmjopen-2018-025556 on 15 October 2019. Downloaded from 
